65384-99-8

Usage

Uses

Used in Pharmaceutical Industry:
(4-phenyl-1,3-thiazol-2-yl)methanol is used as a key intermediate in the synthesis of various pharmaceutical compounds for its potential anti-inflammatory and anti-cancer properties. Its unique molecular structure, which includes both a thiazole and a phenyl group, makes it a promising candidate for the development of new drugs targeting a range of diseases.
Used in Agrochemical Industry:
In the agrochemical sector, (4-phenyl-1,3-thiazol-2-yl)methanol is utilized as a building block in the creation of novel agrochemicals. Its potential biological activities, such as anti-inflammatory properties, can be harnessed to develop new pesticides or other agricultural chemicals that can improve crop yields and protect plants from diseases and pests.
Used in Research and Development:
(4-phenyl-1,3-thiazol-2-yl)methanol is employed as a subject of research in various scientific fields, including medicinal chemistry and biochemistry. Its unique structure and potential biological activities make it an interesting target for exploring new therapeutic agents and understanding the underlying mechanisms of its actions.
Used in Drug Delivery Systems:
Similar to gallotannin, (4-phenyl-1,3-thiazol-2-yl)methanol may also benefit from novel drug delivery systems to enhance its applications and efficacy. The development of organic and metallic nanoparticles as carriers for (4-phenyl-1,3-thiazol-2-yl)methanol could improve its delivery, bioavailability, and therapeutic outcomes, particularly in the context of its anti-cancer properties.

Upstream product

• 75390-44-2 4-Phenyl-2-Thiazolecarboxaldehyde 
• 31877-30-2 ethyl 4-phenyl-1,3-thiazole-2-carboxylate 
• 40235-62-9 2-acetoxythioacetamide 
• 70-11-1 α-bromoacetophenone 
• 110704-59-1 (4-phenylthiazol-2-yl)methyl benzoate 
• 858009-07-1 2-ethoxymethyl-4-phenyl-thiazole 

Downstream Products

• 110703-77-0 [4-Oxo-3-(4-phenyl-thiazol-2-ylmethyl)-3,4-dihydro-phthalazin-1-yl]-acetic acid 
• 65385-00-4 2-chloromethyl-4-phenylthiazole 
• 1476847-59-2 2-Methoxy-6-(6-methoxy-4-((4-phenylthiazol-2-yl)methoxy)benzofuran-2-yl)imidazo[2,1-b][1,3,4]thiadiazole 
• 59020-44-9 4-phenylthiazole-2-carboxylic acid 
• 78502-79-1 2-(bromomethyl)-4-phenylthiazole 
• 75390-44-2 4-Phenyl-2-Thiazolecarboxaldehyde 

Relevant academic research and scientific papers

Design, synthesis and Structure-activity relationship studies of new thiazole-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes

The free fatty acid receptor 1 (FFA1/GPR40) has attracted interest as a novel target for the treatment of type 2 diabetes. Several series of FFA1 agonists including TAK-875, the most advanced compound terminated in phase III studies due to concerns about liver toxicity, have been hampered by relatively high molecular weight and lipophilicity. Aiming to develop potent FFA1 agonists with low risk of liver toxicity by decreasing the lipophilicity, the middle phenyl of TAK-875 was replaced by 11 polar five-membered heteroaromatics. Subsequently, systematic exploration of SAR and application of molecular modeling, leads to the identification of compound 44, which was an excellent FFA1 agonist with robustly hypoglycemic effect both in normal and type 2 diabetic mice, low risks of hypoglycemia and liver toxicity even at the twice molar dose of TAK-875. Meanwhile, two important findings were noted. First, the methyl group in our thiazole series occupied a small hydrophobic subpocket which had no interactions with TAK-875. Furthermore, the agonistic activity revealed a good correlation with the dihedral angle between thiazole core and the terminal benzene ring. These results promote the understanding of ligand-binding pocket and might help to design more promising FFA1 agonists.

COMPOUNDS AND METHODS for the inhibition of HDAC

Disclosed are compounds having the formula: wherein X1, X2, X3, R1, R2, R3, R4, Y, A, Z, L and n are as defined herein, and methods of making and using the same.

IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION

The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.

PAR4 AGONIST PEPTIDES

The present invention provides PAR4 agonist peptides. These peptides are useful for developing robust PAR4 receptor assays.

HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF

Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes

2″-deoxy hygromycin derivatives

This invention relates to compounds of the formula and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R1and R2are as defined herein. The compounds of formula 1 are antibacterial and antiprotozoal agents that may be used to treat various bacterial and protozoal infections and disorders related to such infections. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of treating bacterial and protozoal infections by administering the compounds of formula 1.

HETEROCYCLIC OXOPHTHALAZINYL ACETIC ACIDS

A heterocyclic oxophthalazinyl acetic acid having aldose reductast inhibitory activity of the formula, wherein X is oxygen or sulfur; Z is a covalent bond, O, S, NH or CH2 or CHR5Z is vinyl; R1 is hydroxy, or a prodrug group; R2 is a heterocyclic group, R3 and R4 are hydrogen or the same or a different substituent, and R5 is hydrogen, methyl or trifluoromethyl. The pharmaceutically acceptable acid addition salts of the above compounds wherein R1 is di(C1-C4)alkylamino or (C1-C4)alkoxy substituted by N-morpholino or di(Cl-C4)alkylamino and the pharmaceutically active base addition salts of the above compounds wherein R1 is hydroxy are also aldose reductase inhibitors

Phenylpiperazine derivatives

Phenylpiperazine derivatives of formula (I): STR1 where R1 is benzyl, C1-6 alkyl or optionally substituted phenyl; R2 is optionally substituted phenyl; R3 is hydrogen or C1-4 alkyl; Q is furan, thioph